REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

Kezar Life Sciences (NASDAQ:KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

FDA placed Kezar’s lupus nephritis drug on clinical hold after four fatal adverse events. Kezar says the autoimmune hepatitis ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase ...

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology’s (ACR) annual meeting, ACR ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...